Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II

Clinical Pharmacokinetics

Volumn 48, Issue 12, 2009, Pages 761-804

  Zhou, Shu Feng ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CHLORPHENIRAMINE; CITALOPRAM; CODEINE; CYTOCHROME P450 2D6; DIHYDROCODEINE; DOLASETRON MESILATE; DONEPEZIL; GALANTAMINE; HALOPERIDOL; HYDROCODONE; LORATADINE; MIANSERIN; NEUROLEPTIC AGENT; NICERGOLINE; ONDANSETRON; OXYCODONE; PERPHENAZINE; PHENFORMIN; QUINIDINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; THIORIDAZINE; TOLTERODINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZUCLOPENTHIXOL;

ABDOMINAL PAIN; AKATHISIA; ALLERGIC RHINITIS; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BREAST CANCER; CANCER PAIN; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; COUGHING; DECREASED APPETITE; DEPRESSION; DIZZINESS; DNA POLYMORPHISM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DYSMENORRHEA; DYSTONIA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; IMPOTENCE; INSOMNIA; LACTIC ACIDOSIS; LETHARGY; LIBIDO DISORDER; LOW DRUG DOSE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NIGHTMARE; PAIN; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PULSE RATE; REVIEW; SCHIZOPHRENIA; SEIZURE; SENILE DEMENTIA; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; URTICARIA; WEIGHT REDUCTION; XEROSTOMIA;

ANALGESICS, OPIOID; ANIMALS; ANTIEMETICS; CYTOCHROME P-450 CYP2D6; GENOTYPE; HISTAMINE ANTAGONISTS; HUMANS; MENTAL DISORDERS; MUSCARINIC ANTAGONISTS; PHENOTYPE; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 70449371633     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11318070-000000000-00000     Document Type: Review

References (455)

1. Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009; 48: 689-723
2. Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: clinical and interethnic aspects. Clin Pharmacol Ther 2007; 82: 606-609
3. Hollister LE. Tricyclic antidepressants (firstoftwo parts). N EnglJ Med 1978; 299: 1106-1109
4. Mellstrom B, von Bahr C. Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab Dispos 1981; 9: 565-568
5. Venkatakrishnan K, Von Moltke LL, Obach RS, etal. Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 2000; 293: 343-350
6. Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 2001; 41: 1043-1054 (Pubitemid 32880131)
7. Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic an-tidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997; 25: 740-744
8. Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and ami-triptylinoxide in man. Drug Metab Rev 2004; 36: 723-746
9. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline meta-bolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350-358
10. Dahl ML, Nordin C, Bertilsson L. Enantioselective hydroxylation of nor-triptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit 1991; 13: 189-194
11. Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants: em-phasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995; 28: 26-40
12. Mellstrom B, Sawe J, Bertilsson L, et al. Amitriptyline metabolism: associa-tion with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther 1986; 39: 369-371
13. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psy-chopharmacology (Berl) 1996; 123: 315-319
14. Mellstrom B, Bertilsson L, Sawe J, et al. E-and Z-10-hydroxylation of nor-triptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981; 30: 189-193
15. Gram LF, Brosen K, Kragh-Sorensen P, et al. Steady-state plasma levels of E-and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989; 11: 508-514
16. Dalen P, Dahl ML, Bernal Ruiz ML, et al. 10-Hydroxylation of nortriptyline in White persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-452
17. Yue QY, Zhong ZH, Tybring G, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998; 64: 384-390
18. Morita S, Shimoda K, Someya T, et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psycho-pharmacol 2000; 20: 141-149
19. Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol 2008; 65: 134-138
20. Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376-385
21. Roberts RL, Mulder RT, Joyce PR, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004; 19: 17-23
22. van der Kuy PH, Hooymans PM. Nortriptyline intoxication induced by ter-binafine. BMJ 1998; 316: 441
23. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478-480
24. Peters II MD, Davis SK, Austin LS. Clomipramine: an antiobsessional tri-cyclic antidepressant. Clin Pharm 1990; 9: 165-178
25. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991; 20: 447-462
26. Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomi-pramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996; 277: 1659-1664
27. Nielsen KK, Brosen K, Hansen MG, et al. Single-dose kinetics of clomipra-mine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55: 518-527
28. Nielsen KK, Brosen K, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. Eur J Clin Pharmacol 1992; 43: 405-411
29. Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms: a double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683-691
30. Pinder RM, Brogden RN, Speight TM, et al. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977; 13: 161-218
31. Shu YZ, Hubbard JW, Cooper JK, et al. The identification of urinary me-tabolites of doxepin in patients. Drug Metab Dispos 1990; 18: 735-741
32. Haritos VS, Ghabrial H, Ahokas JT, et al. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E-and Z-doxepin. Pharma-cogenetics 2000; 10: 591-603
33. Hartter S, Tybring G, Friedberg T, et al. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 2002; 19: 1034-1037
34. Kirchheiner J, Meineke I, Muller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E-and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12: 571-580
35. Koski A, Ojanpera I, Sistonen J, et al. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol 2007; 28: 259-261
36. Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desi-pramine. Clin Pharmacokinet 1990; 18: 346-364
37. Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993; 43: 827-832
38. Koyama E, Chiba K, Tani M, et al. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997; 281: 1199-1210
39. BrosenK, Zeugin T, Meyer UA. Roleof P450IID6, the targetofthe sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991; 49: 609-617
40. Nakajima M, Tanaka E, Kobayashi T, et al. Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2002; 30: 636-642
41. Koyama E, Kikuchi Y, Echizen H, et al. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipra-mine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics. Ther Drug Monit 1993; 15: 224-235
42. Brosen K, Otton SV, Gram LF. Imipramine demethylation and hydroxyla-tion: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986; 40: 543-549
43. Spina E, Steiner E, Ericsson O, et al. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1987; 41: 314-319 (Pubitemid 17034185)
44. Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desi-pramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 1987; 42: 278-282
45. Spina E, Gitto C, Avenoso A, et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51: 395-398 (Pubitemid 27055908)
46. Shimoda K, Morita S, Hirokane G, et al. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol Toxicol 2000; 86: 245-249
47. Brosen K, Klysner R, Gram LF, et al. Steady-state concentrations of imi-pramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986; 30: 679-684
48. Sindrup SH, Brosen K, Gram LF. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther Drug Monit 1990; 12: 445-449
49. Schenk PW, van Fessem MA, Verploegh-Van Rij S, et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008; 13: 597-605
50. Pinder RM, Brogden RN, Speight TM, et al. Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs 1977; 13: 321-352
51. Brachtendorf L, Jetter A, Beckurts KT, et al. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 2002; 90: 144-149
52. Breyer-Pfaff U, Kroeker M, Winkler T, et al. Isolation and identification of hydroxylated maprotiline metabolites. Xenobiotica 1985; 15: 57-66
53. Hartter S, Wetzel H, Hammes E, et al. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 1993; 110: 302-308
54. Normann C, Lieb K, Walden J. Increased plasma concentration of mapro-tiline by coadministration of risperidone. J Clin Psychopharmacol 2002; 22: 92-94
55. Konig F, Wolfersdorf M, Loble M, et al. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression. Pharmacopsychiatry 1997; 30: 125-127
56. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670-677
57. Firkusny L, Gleiter CH. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debri-soquine. Br J Clin Pharmacol 1994; 37: 383-388
58. Gastpar M. Clinical originality and new biology of trimipramine. Drugs 1989; 38 Suppl. 1: 43-8; discussion 49-50
59. Bolaji OO, Coutts RT, Baker GB. Metabolism of trimipramine in vitro by human CYP2D6 isozyme. Res Commun Chem Pathol Pharmacol 1993; 82: 111-120
60. Eap CB, Bender S, Gastpar M, et al. Steady state plasma levels of the en-antiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22: 209-214
61. Kirchheiner J, Muller G, Meineke I, et al. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23: 459-466
62. Eap CB, Laurian S, Souche A, et al. Influence of quinidine on the pharma-cokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers: a pilot study on two subjects. Neuropsychobiology 1992; 25: 214-220
63. Leinonen E, Koponen HJ, Lepola U. Paroxetine increases serum trimipra-mine concentration: a report of two cases. Human Psychopharmacol Clin Exp 2004; 10: 345-347
64. Musshoff F, Schmidt P, Madea B. Fatality caused by a combined trimipra-mine-citalopram intoxication. Forensic Sci Int 1999; 106: 125-131
65. Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34: 281-302
66. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake in-hibitors. Pharmacol Ther 2000; 85: 11-28
67. Preskorn SH. Clinically relevant pharmacology of selective serotonin re-uptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21
68. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O-and N-demethyla-tion of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI anti-depressants. Neuropsychopharmacology 1999; 20: 480-490
69. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46: 281-290
70. Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59: 298-309
71. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating bio-transformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-1109
72. Herrlin K, Yasui-Furukori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003; 56: 415-421
73. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 2008; 3: e1872
74. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit 2003; 25: 183-191
75. Figgitt DP, McClellan KJ. Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs 2000; 60: 925-954
76. Wilde MI, Plosker GL, Benfield P. Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46: 895-924
77. Spigset O, Granberg K, Hagg S, et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45: 257-263
78. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175-190
79. Spigset O, Axelsson S, Norstrom A, et al. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001; 57: 653-658
80. DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997; 58 Suppl. 5: 7-14
81. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29 Suppl. 1: 1-9
82. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30: 1206-1227
83. WagnerW, Vause EW. Fluvoxamine: a review of global drug-drug interaction data. Clin Pharmacokinet 1995; 29 Suppl. 1: 26-31; discussion 31-32
84. Christensen M, Tybring G, Mihara K,et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002; 71: 141-152
85. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvox-amine-induced side effects in Japanese depressed patients. Neuropsycho-pharmacology 2006; 31: 825-831
86. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards sub-population-specific dosages. Acta Psychiatr Scand 2001; 104: 173-192
87. Mandrioli R, Forti GC, Raggi MA. Fluoxetine metabolism and pharmaco-logical interactions: the role of cytochrome P450. Curr Drug Metab 2006; 7: 127-133
88. Margolis JM, O'Donnell JP, Mankowski DC, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 1187-1191
89. Ring BJ, Eckstein JA, Gillespie JS, et al. Identification of the human cyto-chromes P450 responsible for in vitro formation of R-and S-norfluoxetine. J Pharmacol Exp Ther 2001; 297: 1044-1050
90. Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60: 512-521
91. Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacoge-netics 1999; 9: 55-60
92. Scordo MG, Spina E, Dahl ML, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97: 296-301
93. Stedman CA, Begg EJ, Kennedy MA, et al. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002; 17: 187-190
94. Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharma-cology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55: 85-120
95. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33: 521-523
96. Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-287
97. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-295
98. Ozdemir V, Tyndale RF, Reed K, et al. Paroxetine steady-state plasma con-centration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol 1999; 19: 472-475
99. Lam YW, Gaedigk A, Ereshefsky L, et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22: 1001-1006
100. Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003; 25: 738-742
101. Zourkova A, Hadasova E. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. J Sex Marital Ther 2002; 28: 451-461
102. Murphy Jr GM, Kremer C, Rodrigues S, et al. Pharmacogenetics of anti-depressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835
103. Tanaka M, Kobayashi D, Murakami Y, et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11: 261-267
104. Pinder RM, Van Delft AM. The potential therapeutic role of the enantiomers and metabolites of mianserin. Br J Clin Pharmacol 1983; 15 Suppl. 2: 269-76S
105. Delbressine LP, Moonen ME, Kaspersen FM, et al. Biotransformation of mianserin in laboratory animals and man. Xenobiotica 1992; 22: 227-236
106. Stormer E, von Moltke LL, Shader RI, et al. Metabolism of the anti-depressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28: 1168-1175
107. Koyama E, Chiba K, Tani M, et al. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin en-antiomers. J Pharmacol Exp Ther 1996; 278: 21-30
108. Dahl ML, TybringG, Elwin CE, etal. Stereoselective disposition ofmianserin is related todebrisoquin hydroxylation polymorphism. Clin Pharmacol Ther 1994; 56: 176-183
109. Yasui N, Tybring G, Otani K, et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 1997; 7: 369-374
110. Sindrup SH, Tuxen C, Gram LF, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251-255
111. Tacke U, Leinonen E, Lillsunde P, et al. Debrisoquine hydroxylation phe-notypes of patients with high versus low to normal serum antidepressant concentrations. J Clin Psychopharmacol 1992; 12: 262-267
112. Begg EJ, Sharman JR, Kidd JE, et al. Variability in the elimination of mianserin in elderly patients. Br J Clin Pharmacol 1989; 27: 445-451
113. Mihara K, Otani K, Tybring G, et al. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol 1997; 17: 467-471
114. Anttila SA, Leinonen EV. Areview of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7: 249-264
115. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirta-zapine. Clin Pharmacokinet 2000; 38: 461-474
116. Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig 1998; 15: 45-55
117. Grasmader K, Verwohlt PL, Kuhn KU, et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004; 60: 473-480
118. Kirchheiner J, Henckel HB, Meineke I, et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004; 24: 647-652
119. Brockmoller J, Meineke I, Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 2007; 81: 699-707
120. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280-294
121. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994; 51: 3033-3046
122. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is cata-lysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-156
123. Lindh JD, Annas A, Meurling L, et al. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003; 59: 401-406
124. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435-443
125. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202-208
126. Fukuda T, Nishida Y, Zhou Q, et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000; 56: 175-180 (Pubitemid 30341393)
127. Eap CB, Lessard E, Baumann P, et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003; 13: 39-47
128. Whyte EM, Romkes M, Mulsant BH, et al. CYP2D6 genotype and venla-faxine-XR concentrationsindepressed elderly. IntJGeriatr Psychiatry 2006; 21: 542-549
129. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31: 493-502
130. Hermann M, Hendset M, Fosaas K, et al. Serum concentrations of venla-faxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenla- faxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 2008; 64: 483-487
131. McAlpine DE, O'Kane DJ, Black JL, et al. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc 2007; 82: 1065-1068
132. Xu ZH, Wang W, Zhao XJ, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver mi-crosomes. Br J Clin Pharmacol 1999; 48: 416-423
133. Bertilsson L, Mellstrom B, Sjokvist F, et al. Slow hydroxylation of nor-triptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1981; 1: 560-561
134. Bluhm RE, Wilkinson GR, Shelton R, et al. Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther 1993; 53: 89-95
135. Bertilsson L, Dahl ML, Sjoqvist F, et al. Molecular basis for rational mega-prescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63
136. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants. A pilot study. Clin Pharmacol Ther 2004; 75: 386-393
137. Kawanishi C, Lundgren S, Agren H, et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803-807
138. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329-336
139. Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 poly-morphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008; 65: 558-564
140. Kwadijk-de Gijsel S, Bijl MJ, Visser LE, et al. Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants. Br J Clin Pharmacol 2009; 68: 221-225
141. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med 2008; 28: 619-626
142. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: com-parison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358-403
143. Worrel JA, Marken PA, Beckman SE, et al. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000; 57: 238-255
144. Vohora D. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Curr Opin Investig Drugs 2007; 8: 531-8
145. Moller HJ. Risperidone: a review. Expert Opin Pharmacother 2005; 6: 803-18
146. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008; 68: 2269-2292
147. Gardiner SJ, Begg EJ. Pharmacogenetics drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521-590
148. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J 2005; 5: 6-13
149. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008; 9: 738-784
150. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schi-zophrenia and schizoaffective disorder. Drugs 2004; 64: 1715-1736
151. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsycho- pharmacology 2003; 28: 1400-1411
152. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of ar-ipiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28: 744-749
153. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20: 55-64
154. Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008; 66: 802-810
155. Koue T, Kubo M, Funaki T, et al. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. Biol Pharm Bull 2007; 30: 2154-2158
156. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007; 22: 358-366
157. Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63: 1147-1151
158. Oosterhuis M, Van De Kraats G, Tenback D. Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient. Am J Psychiatry 2007; 164: 175
159. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009; 31: 233-238
160. Hartmann F, Gruenke LD, Craig JC, et al. Chlorpromazine metabolism in extracts of liver and small intestine from guinea pig and from man. Drug Metab Dispos 1983; 11: 244-248
161. Yoshii K, Kobayashi K, Tsumuji M, et al. Identification of human cyto-chrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 2000; 67: 175-184
162. Muralidharan G, Cooper JK, Hawes EM, et al. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debriso-quine. Eur J Clin Pharmacol 1996; 50: 121-128
163. Sunwoo YE, Ryu J, Jung H, et al. Disposition of chlorpromazine in Korean healthy subjects with CYP2D6 wild-type and *10B mutation [abstract]. Clin Pharmacol Ther 2004; 73: PII-146
164. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Phar-macokinet 1999; 37: 435-456
165. Yatham LN. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry 2002; 63: 10-14
166. Tateishi T, Watanabe M, Kumai T, et al. CYP3A is responsible for N-deal-kylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 2000; 67: 2913-2920
167. Kudo S, Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 1998; 54: 253-259
168. Pan LP, De Vriendt C, Belpaire FM. In-vitro characterization of the cyto-chrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998; 8: 383-389
169. Kim YH, Cha IJ, Shim JC, et al. Effect of rifampin on the plasma con-centration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. J Clin Psychopharmacol 1996; 16: 247-252
170. Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997; 35: 335-339
171. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: in-teraction studies with amitriptyline, clomipramine and neuroleptics in phe-notyped patients. Pharmacol Res 1995; 31: 347-353
172. Ulrich S, Wurthmann C, Brosz M, et al. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998; 34: 227-263 (Pubitemid 28112401)
173. Lane HY, Hu OY, Jann MW, et al. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res 1997; 69: 105-111
174. Llerena A, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 92-97
175. Llerena A, Dahl ML, Ekqvist B, etal. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14: 261-264
176. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173-178
177. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452
178. Panagiotidis G, Arthur HW, Lindh JD, et al. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit 2007; 29: 417-422
179. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7: 415-418 (Pubitemid 27427554)
180. Mihara K, Suzuki A, Kondo T, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 1999; 65: 291-294 (Pubitemid 29142935)
181. Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52: 265-271
182. Park JY, Shon JH, Kim KA, et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharma-codynamics of haloperidol in healthy subjects. J Clin Psychopharmacol 2006; 26: 135-142
183. Shimoda K, Morita S, Yokono A, et al. CYP2D6*10 alleles are not the de-terminant of the plasma haloperidol concentrations in Asian patients. Ther Drug Monit 2000; 22: 392-396
184. Ohnuma T,Shibata N,MatsubaraY,et al. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br J Clin Pharmacol 2003; 56: 315-320
185. Pan L, Vander Stichele R, Rosseel MT, et al. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic in-patients. Ther Drug Monit 1999; 21: 489-497
186. Someya T, Suzuki Y, Shimoda K, et al. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin Neurosci 1999; 53: 593-597
187. Hartung B, Wada M, Laux G, et al. Perphenazine for schizophrenia. Cochrane Database Syst Rev 2005; (1): CD003443
188. Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 2000; 50: 563-571
189. Bertilsson L, Dahl ML, Ekqvist B, et al. Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. Psychopharmacol Ser 1993; 10: 230-237
190. Dahl-Puustinen ML, Liden A, Alm C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78-81
191. Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996; 60: 41-47 (Pubitemid 26279219)
192. Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclo-penthixol. Clin Pharmacol Ther 1996; 59: 423-428
193. Ozdemir V, Bertilsson L, Miura J, et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17: 339-347
194. Aklillu E, Kalow W, Endrenyi L, et al. CYP2D6 and DRD2 genes differen-tially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 2007; 17: 989-993
195. Bushe C, Shaw M, Peveler RC. A review of the association between anti-psychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22: 46-55
196. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis inthe treatment of schizophrenia. J Psychopharmacol 2008; 22: 70-75
197. Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperpro-lactinaemia: clinical recommendations. J Psychopharmacol 2008; 22: 98-103
198. Molitch ME. Drugs and prolactin. Pituitary 2008; 11: 209-18
199. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: me-chanisms, clinical features and management. Drugs 2004; 64: 2291-2314
200. Yu AM, Idle JR, Byrd LG, et al. Regeneration of serotonin from 5-methox-ytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173-181
201. Ozdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cyto-chrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334-347
202. Pollock BG, Mulsant BH, Sweet RA, et al. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31: 327-331
203. Fenton C, Scott LJ. Risperidone: a review of its usein the treatment of bipolar mania. CNS Drugs 2005; 19: 429-444
204. Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253-273 (Pubitemid 24260357)
205. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134-1141
206. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29: 1263-1268
207. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000; 22: 481-485
208. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraco-nazole affects plasma concentrations of risperidone and 9-hydro-xyrisperidone inschizophrenic patients. Clin Pharmacol Ther 2005; 78: 520-528
209. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57-73
210. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001; 23: 223-227
211. Mannheimer B, Bahr CV, Pettersson H, et al. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther Drug Monit. Epub 2008 Aug 23
212. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999; 147: 300-305
213. Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the phar-macokinetics and safety of risperidone in psychotic patients. Pharma-copsychiatry 2002; 35: 50-56
214. Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998; 20: 380-384
215. Nyberg S, Dahl ML, Halldin C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 1995; 119: 345-348
216. Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001; 57: 671-675
217. Guzey C, Aamo T, Spigset O. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J Clin Psychiatry 2000; 61: 600-601
218. De Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27
219. Wojcikowski J, Maurel P, Daniel WA. Characterization of human cyto-chrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 2006; 34: 471-476
220. Llerena A, Berecz R,dela Rubia A, etal. Use of the mesoridazine/ thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 2000; 22: 397-401
221. Berecz R, de la Rubia A, Dorado P, et al. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59: 45-50
222. Eap CB, Guentert TW, Schaublin-Loidl M, et al. Plasma levels of the en-antiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dex-tromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322-331
223. Llerena A, Berecz R, dela Rubia A, etal. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 2002; 16: 361-364
224. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234-240
225. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev 2005; (4): CD005474
226. Dahl ML, Ekqvist B, Widen J, et al. Disposition of the neuroleptic zuclo-penthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99-102
227. LinnetK, Wiborg O. Influence of CYP2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1996; 18: 629-634
228. Jaanson P, Marandi T, Kiivet RA, et al. Maintenance therapy with zuclo-penthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002; 162: 67-73
229. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for thein vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658-666
230. Olesen OV, Linnet K. Contributionsoffive human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832
231. Schaber G, Wiatr G, Wachsmuth H, et al. Isolation and identification of clozapine metabolites in patient urine. Drug Metab Dispos 2001; 29: 923-931
232. Breyer-Pfaff U, Wachsmuth H. Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine. Drug Metab Dispos 2001; 29: 1343-1348
233. Hagg S, Spigset O, Lakso HA, et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001; 57: 493-497
234. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119-127
235. Melkersson KI, Scordo MG, Gunes A, etal. Impactof CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 2007; 68: 697-704
236. Dettling M, Sachse C, Muller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000; 33: 218-220
237. Uehlinger C, Crettol S, Chassot P, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol 2007; 27: 273-278
238. Plesnicar BK, Zalar B, Breskvar K, et al. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 2006; 20: 829-833
239. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246-251
240. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-470
241. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118-121
242. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmaco-genet Genomics 2005; 15: 151-158
243. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007; 81: 899-902
244. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharma-codynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-739
245. Spaldin V, Madden S, Pool WF, et al. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38: 15-22
246. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998; 32: 70-77
247. Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the anti-dementia drug galanthamine is catalysed by cytochrome P450 2D6. Phar-macogenetics 1999; 9: 661-8
248. Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007; 8: 1011-23
249. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 poly-morphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 2006; 62: 721-726
250. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004; 19: 624-633
251. Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46 Suppl. 1: 19-24
252. Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res 2007; 4: 479-500
253. Pilotto A, Franceschi M, D'Onofrio G, et al. Effect of a CYP2D6 poly-morphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009; 73: 761-767
254. Gaedigk A, Ryder DL, Bradford LD, et al. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the-1584G promoter polymorphism. Clin Chem 2003; 49: 1008-1011
255. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792
256. Westra P, van Thiel MJ, Vermeer GA, et al. Pharmacokinetics of galantha-mine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 1986; 58: 1303-1307
257. Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002; 30: 553-563
258. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 2004; 61: 2391-2399
259. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004; 64: 205-222
260. Ring BJ, Gillespie JS, Eckstein JA, et al. Identification of the human cyto-chromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002; 30: 319-323
261. Farid NA, Bergstrom RF, Ziege EA, et al. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985; 25: 296-301
262. Paulzen M, Clement HW, Grunder G. Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol 2008; 11: 289-291
263. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31: 98-107
264. Cui YM, Teng CH, Pan AX, et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Br J Clin Pharmacol 2007; 64: 445-449
265. Shen H, He MM, Liu H, et al. Comparative metabolic capabilities and in-hibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 2007; 35: 1292-1300
266. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46: 242-251
267. Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol 2008; 18: 79-86
268. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: E83
269. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50-55
270. Tamayo JM, Pumariega A, Rothe EM, et al. Latino versus Caucasian re-sponse to atomoxetine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008; 18: 44-53
271. Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging 2007; 2: 327-335
272. Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig 2008; 28: 533-552
273. ArcamoneF,Glasser AG, GrafnetterovaJ, etal. Studies on the metabolism of ergoline derivatives: metabolism of nicergoline in man and in animals. Biochem Pharmacol 1972; 21: 2205-2213
274. Bottiger Y, Dostert P, Benedetti MS, et al. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol 1996; 42: 707-711
275. Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol 2001; 19: 312-318
276. Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 289-293
277. Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169-172
278. Brynne N, Forslund C, Hallen B, et al. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999; 48: 564-572
279. Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic oftolterodine. Clin Pharmacol Ther 1998; 63: 529-539
280. Brynne N, Bottiger Y, Hallen B, et al. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omepra-zole. Br J Clin Pharmacol 1999; 47: 145-150
281. Brynne N, Svanstrom C, Aberg-Wistedt A, et al. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 1999; 48: 553-563
282. Olsson B, Szamosi J. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001; 40: 135-143
283. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolter-odine. Clin Pharmacokinet 2001; 40: 227-235 (Pubitemid 32324452)
284. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-2494
285. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which an-tiemetic for which therapy? Oncology (Williston Park) 2007; 21: 946-53; discussion 954, 959, 962 passim
286. Aapro M. 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 2005; 69: 97-109
287. Aapro M, Blower P. 5-Hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents? Cancer 2005; 104: 1-18
288. Evangelista S. Eziopitant: Pfizer. Curr Opin Investig Drugs 2001; 2: 1441-3
289. Fischer V, Baldeck JP, Tse FL. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 1992; 20: 603-607
290. Kutz K. Pharmacology, toxicology and human pharmacokinetics of tropi-setron. Ann Oncol 1993; 4 Suppl. 3: 15-18
291. Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22: 269-274
292. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 en-zymes involved in the in vitro metabolism of dolasetron: comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996; 24: 602-609
293. Obach RS. Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction. Drug Metab Dis-pos 2001; 29: 1057-1067
294. Desta Z, Wu GM, Morocho AM, et al. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002; 30: 336-343
295. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-189
296. Obach RS. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 2000; 28: 1069-1076
297. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32: 1287-1292
298. Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and ther-apeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs 1997; 54: 273-298
299. Reith MK, Sproles GD, Cheng LK. Human metabolism of dolasetron me-sylate, a 5-HT3 receptor antagonist. Drug Metab Dispos 1995; 23: 806-812
300. Janicki PK, Schuler HG, Jarzembowski TM, et al. Prevention of post-operative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg 2006; 102: 1127-1133
301. Milne RJ, Heel RC. Ondansetron: therapeutic use as an antiemetic. Drugs 1991; 41: 574-595
302. Ashforth EI, Palmer JL, Bye A, et al. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994; 37: 389-391
303. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmaco-genomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005; 102: 543-549
304. Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000; 59: 1297-1315
305. Lee CR, Plosker GL, McTavish D. Tropisetron: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925-943
306. Firkusny L, Kroemer HK, Eichelbaum M. In vitro characterization of cyto-chrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem Pharmacol 1995; 49: 1777-1784
307. Kim MK, Cho JY, Lim HS, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol 2003; 59: 111-116
308. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805-2811
309. Oppenheimer JJ, Casale TB. Next generation antihistamines: therapeutic rationale, accomplishments and advances. Expert Opin Investig Drugs 2002; 11: 807-817
310. Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacody-namics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet 2008; 47: 217-230
311. Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine: formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996; 51: 165-172
312. Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine. Int Arch Allergy Immunol 1995; 107: 420
313. Nakamura K, Yokoi T, Inoue K, et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist pro-methazine in human liver microsomes. Pharmacogenetics 1996; 6: 449-457
314. Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol 2001; 51: 133-142
315. Nakamura K, Yokoi T, Kodama T, et al. Oxidation of histamine H1 an-tagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther 1998; 284: 437-442
316. Jones BC, Hyland R, Ackland M, et al. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metab Dispos 1998; 26: 875-882
317. Imai T, Taketani M, Suzu T, et al. In vitro identification of the human cyto-chrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos 1999; 27: 942-946
318. Nakajima M, Nakamura S, Tokudome S, et al. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 1999; 27: 1381-1391
319. Goto A, Ueda K, Inaba A, et al. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull 2005; 28: 328-334
320. Goto A, Adachi Y, Inaba A, et al. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull 2004; 27: 684-690
321. Kishimoto W, Hiroi T, Sakai K, et al. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997; 98: 273-292
322. Narimatsu S, Kariya S, Isozaki S, et al. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem Biophys Res Commun 1993; 193: 1262-1268
323. Kariya S, Isozaki S, Uchino K, et al. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull 1996; 19: 1511-1514
324. Akutsu T, Kobayashi K, Sakurada K, et al. Identification of human cyto-chrome P450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 2007; 35: 72-78
325. He N, Zhang WQ, Shockley D, et al. Inhibitory effects of H1-antihistamines on CYP2D6-and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 2002; 57: 847-851
326. Yasuda SU, Zannikos P, Young AE, et al. The roles of CYP2D6 and ste-reoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 2002; 53: 519-525
327. Tran VT, Chang RS, Snyder SH. Histamine H1. receptors identified in mammalian brain membranes with [3H]mepyramine. Proc Natl Acad Sci U S A 1978; 75: 6290-6294
328. Peets EA, Jackson M, Symchowicz S. Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 1972; 180: 364-374
329. Yasuda SU, Wellstein A, Likhari P, et al. Chlorpheniramine plasma con-centration and histamine H1-receptor occupancy. Clin Pharmacol Ther 1995; 58: 210-220
330. Banerji A, Long AA, Camargo CA, et al. Diphenhydramine versus non-sedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc 2007; 28: 418-426
331. McGeer PL, Boulding JE, Gibson WC, et al. Drug-induced extrapyramidal reactions: treatment with diphenhydramine hydrochloride and dihydrox- yphenylalanine. JAMA 1961; 177: 665-670
332. Chang T, Okerholm RA, Glazko AJ. Identification of diphenydramine (Benadryl) metabolities in human subjects. Res Commun Chem Pathol Pharmacol 1974; 9: 391-404
333. Blyden GT, Greenblatt DJ, Scavone JM, et al. Pharmacokinetics of di-phenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 1986; 26: 529-533
334. Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. Curr Drug Metab 2003; 4: 105-129
335. Breyer-Pfaff U, Fischer D, Winne D. Biphasic kinetics of quaternary am-monium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Drug Metab Dispos 1997; 25: 340-345
336. Fischer D, Breyer-Pfaff U. Variability of diphenhydramine N-glucuronida-tion in healthy subjects. Eur J Drug Metab Pharmacokinet 1997; 22: 151-154
337. Luo H, Hawes EM, McKay G, et al. N+-glucuronidation of aliphatic tertiary amines, a general phenomenon in the metabolism of H1-antihistamines in humans. Xenobiotica 1991; 21: 1281-1288
338. Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activityinhumans. J Clin Psychopharmacol 2001; 21: 175-184
339. Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmaco-logical properties and therapeutic use in allergic disorders. Drugs 1994; 48: 617-637
340. Ramanathan R, Reyderman L, Su AD, et al. Disposition of desloratadine in healthy volunteers. Xenobiotica 2007; 37: 770-787
341. Ramanathan R, Reyderman L, Kulmatycki K, et al. Disposition of loratadine in healthy volunteers. Xenobiotica 2007; 37: 753-769
342. Yin OQ, Shi XJ, Tomlinson B, et al. Effect of CYP2D6*10 allele on the pharmacokinetics of loratadine in Chinese subjects. Drug Metab Dispos 2005; 33: 1283-1287
343. Saruwatari J, Matsunaga M, Ikeda K, et al. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 2006; 62: 995-1001
344. Lotsch J. Opioid metabolites. J Pain Symptom Manage 2005; 29: S10-24
345. Dayer P, Desmeules J, Leemann T, et al. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 1988; 152: 411-416
346. Yue QY, Sawe J. Different effects of inhibitors on the O-and N-demethyla-tion of codeine in human liver microsomes. Eur J Clin Pharmacol 1997; 52: 41-47
347. Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyl-transferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos 2008; 36: 688-694
348. Lotsch J,SkarkeC, LiefholdJ, et al. Genetic predictorsofthe clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharma-cokinet 2004; 43: 983-1013
349. Eckhardt K, Li S, Ammon S,et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27-33
350. Poulsen L, Brosen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-295
351. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996; 278: 1165-1174
352. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabo-lism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7: 375-379
353. Mikus G, Bochner F, Eichelbaum M, et al. Endogenous codeine and mor-phine in poor and extensive metabolisers of the CYP2D6 (debrisoqui-ne/sparteine) polymorphism. J Pharmacol Exp Ther 1994; 268: 546-551
354. Mikus G, Morike K, Griese EU, et al. Relevance of deficient CYP2D6 in opiate dependence. Pharmacogenetics 1998; 8: 565-568
355. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429-444
356. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poi-soning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704
357. Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85: 31-35
358. Edwards JE, McQuay HJ, Moore RA. Single dose dihydrocodeine for acute postoperative pain. Cochrane Database Syst Rev 2000; (4): CD002760
359. Kirkwood LC, Nation RL, Somogyi AA. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 1997; 44: 549-555
360. Fromm MF, Hofmann U, Griese EU, et al. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin Pharmacol Ther 1995; 58: 374-382
361. Wilder-Smith CH, Hufschmid E, Thormann W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihy-dromorphine: a cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol 1998; 45: 575-581
362. Schmidt H, Vormfelde SV, Walchner-Bonjean M, et al. The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther 2003; 41: 95-106
363. Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some com-monly used opioids and their metabolites. Life Sci 1991; 48: 2165-2171
364. Hutchinson MR, Menelaou A, Foster DJ, et al. CYP2D6 and CYP3A4 in-volvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004; 57: 287-297
365. Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54: 463-472
366. Lelas S, Wegert S, Otton SV, et al. Inhibitors of cytochrome P450 differen-tially modify discriminative-stimulus and antinociceptive effects of hydro-codone and hydromorphone in rhesus monkeys. Drug Alcohol Depend 1999; 54: 239-249
367. Kaplan HL, Busto UE, Baylon GJ, et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997; 281: 103-108
368. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmaco-kinetics and pharmacodynamics. J Pain Symptom Manage 1993; 8: 63-67
369. Leow KP, Smith MT, Williams B, et al. Single-dose and steady-state phar-macokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52: 487-495
370. Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal mi-crosomes. Drug Metab Dispos 2004; 32: 447-454
371. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401-409 (Pubitemid 23119426)
372. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64: 603-611
373. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods 1999; 42: 61-66
374. Kristensen K, Christensen CB, Christrup LL. The m1, m2, d, k opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56: PL45-50
375. de Vos JW, Geerlings PJ, van den Brink W, et al. Pharmacokinetics of me-thadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995; 48: 361-366
376. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab Dispos 2003; 31: 742-747
377. Coller JK, Joergensen C, Foster DJ, et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)-and racemic-methadone. Int J Clin Pharmacol Ther 2007; 45: 410-417
378. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668-681
379. Shiran MR, Chowdry J, Rostami-Hodjegan A, et al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing me-thadone maintenance treatment. Br J Clin Pharmacol 2003; 56: 220-224
380. Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993; 35: 30-34 (Pubitemid 23016955)
381. Begre S, von Bardeleben U, Ladewig D, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22: 211-215
382. Eap CB, Bertschy G, Powell K, et al. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of metha-done. J Clin Psychopharmacol 1997; 17: 113-117
383. Cobb MN, DesaiJ, Brown Jr LS, etal. The effectof fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998; 63: 655-662
384. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmaco-kinet 2004; 43: 879-923
385. Paar WD, Poche S, Gerloff J, et al. Polymorphic CYP2D6 mediates O-de-methylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53: 235-239
386. Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cyto-chrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001; 29: 1146-1155
387. Abdel-Rahman SM, Leeder JS, Wilson JT, et al. Concordance between tra-madol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002; 42: 24-29
388. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tra-madol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-644
389. Enggaard TP, Poulsen L, Arendt-Nielsen L, et al. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006; 102: 146-150
390. Slanar O, Nobilis M, Kvetina J, et al. Miotic action of tramadol is determined by CYP2D6 genotype. Physiol Res 2007; 56: 129-136
391. Fliegert F, Kurth B, Gohler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects: the relationship between pharmacody-namics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 2005; 61: 257-266
392. Wang G, Zhang H, He F, et al. Effect of the CYP2D6*10 C188T poly-morphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62: 927-931
393. Gan SH, Ismail R, Wan Adnan WA, et al. Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. J Clin Pharm Ther 2004; 29: 455-463
394. Halling J, Weihe P, Brosen K.CYP2D6 polymorphism inrelation to tramadol metabolism: a study of Faroese patients. Ther Drug Monit 2008; 30: 271-275
395. Gan SH, Ismail R, Wan Adnan WA, et al. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diagn Ther 2007; 11: 171-181
396. Pedersen RS, Damkier P, Brosen K. Tramadol asa new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 2005; 77: 458-467
397. Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006; 62: 513-521
398. Garcia-Quetglas E, Azanza JR, Sadaba B, et al. Pharmacokinetics of tra-madol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 2007; 55: 122-130
399. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-238
400. Dalen P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19: 543-544
401. De Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psycho-pharmacol 2003; 23: 420-421
402. Kirchheiner J, Keulen JT, Bauer S, et al. Effects of the CYP2D6 gene dupli-cation on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008; 28: 78-83
403. MarchettiP,GiannarelliR, di CarloA, etal. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clin Pharmacokinet 1991; 21: 308-317
404. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relation-ships of oral hypoglycaemic agents. An update. Clin Pharmacokinet 1989; 16: 100-128
405. Oates NS, Shah RR, Idle JR, et al. Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 1982; 32: 81-89
406. Shah RR, Evans DA, Oates NS, et al. The genetic control of phenformin 4-hydroxylation. J Med Genet 1985; 22: 361-366
407. Shah RR, Oates NS, Idle JR, et al. Genetic impairment of phenformin me-tabolism. Lancet 1980; 1: 1147
408. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-241
409. Oates NS, Shah RR, Idle JR, et al. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983; 34: 827-834
410. Oates NS, Shah RR, Idle JR, et al. Phenformin-induced lacticacidosis asso-ciated with impaired debrisoquine hydroxylation. Lancet 1981; 1: 837-838
411. Wiholm BE, Alvan G, Bertilsson L, et al. Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin. Lancet 1981; 1: 1098-1099
412. Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 2008; 630: 206-219
413. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechan-isms of action and application to clinical practice. N Engl J Med 2003; 348: 618-629
414. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and anti-hormonal resistance in breast cancer. J Clin Oncol 2007; 25: 5815-5824
415. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007; 7: 46-53
416. Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-1075
417. Beverage JN, Sissung TM, Sion AM, et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007; 96: 2224-2231
418. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758-1764
419. Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formationof the 4-hydroxy, 40-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hy-droxytamoxifen. Drug Metab Dispos 2002; 30: 869-874
420. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997; 57: 3402-3406
421. Dehal SS, Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydro-xylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 1999; 27: 681-688
422. Ghobadi C, Gregory A, Crewe HK,et al. CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet 2008; 23: 101-105
423. Poon GK, Chui YC, McCague R, et al. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 1993; 21: 1119-1124
424. Jacolot F, Simon I, Dreano Y, et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991; 41: 1911-1919
425. Katzenellenbogen BS, Norman MJ, Eckert RL, et al. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of ta-moxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984; 44: 112-119
426. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39
427. Gjerde J, Hauglid M, Breilid H, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy numberontamoxifen metabolism. Ann Oncol 2008; 19: 56-61
428. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193
429. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-121
430. Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24: 3708-9; author reply 3709
431. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74
432. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen bio-transformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318
433. Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008; 19: 1423-1429
434. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recur-rence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99: 995-999
435. Lim HS, Ju Lee H, Seok Lee K, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25: 3837-3845
436. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in ta-moxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91: 249-258
437. Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7: R284-90
438. Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in post-menopausal patients with breast cancer. Breast Cancer Res 2007; 9: R7
439. Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther 2008; 83: 225-227
440. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83: 160-166
441. Takimoto CH. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? Nat Clin Pract Oncol 2007; 4: 152-153
442. Wennerholm A, Dandara C, Sayi J, et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71: 77-88
443. Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26
444. Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of con-centration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50: 1623-1633
445. Hinrichs JW, Loovers HM, Scholten B, etal. Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur J Clin Pharmacol 2008; 64: 979-986
446. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: trans-lating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-242
447. Gaedigk A, Bradford LD, Alander SW, et al. CYP2D6*36 gene arrangements within theCYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 2006; 34: 563-569
448. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in Black Americans. Clin Pharmacol Ther 2002; 72: 76-89
449. Gaedigk A, Ndjountche L, Gaedigk R, et al. Discovery of a novel nonfunc-tional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects. Clin Pharmacol Ther 2003; 73: 575-576
450. Yamazaki H, Kiyotani K, Tsubuko S, et al. Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab Pharmacokinet 2003; 18: 269-271
451. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89-295
452. Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cyto-chrome P450 2D6. J Biol Chem 2006; 281: 7614-7622
453. Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 2009; 16: 2661-2805
454. Paine MJ, McLaughlin LA, Flanagan JU, et al. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 2003; 278: 4021-4027
455. Mackman R, Tschirret-Guth RA, Smith G, et al. Active-site topologies of human CYP2D6 and its aspartate-301-glutamate, asparagine, and glycine mutants. Arch Biochem Biophys 1996; 331: 134-40